Brief: Adagene Presents Interim Results Of Masked Anti-CTLA-4 SAFEbody ADG126 in Combination with Pembrolizumab in Metastatic Microsatellite-stable Colorectal Cancer

Adagene

16/01/2024 23:17

Jan 16 (Reuters) - Adagene Inc  978y.F :
    * ADAGENE PRESENTS INTERIM RESULTS REINFORCING BEST-IN-CLASS
PROFILE OF MASKED ANTI-CTLA-4 SAFEBODY® ADG126 (MUZASTOTUG) IN
COMBINATION WITH PEMBROLIZUMAB IN METASTATIC
MICROSATELLITE-STABLE (MSS) COLORECTAL CANCER (CRC)
    * ADAGENE INC - DATA FROM ADDITIONAL PATIENTS AT 10 MG/KG
Q3W
DOSING REGIMEN EXPECTED THROUGHOUT 2024
    * ADAGENE INC - DATA FROM FIRST TRANCHE OF MSS CRC PATIENTS
TREATED WITH ADG126 10 MG/KG EVERY THREE WEEKS IN DOSE EXPANSION
SHOWED CLINICAL BENEFIT
    * ADAGENE-PRELIM SURVIVAL ANALYSIS OF ADG126 10 MG/KG DOSING
REGIMENS IN PATIENTS WITHOUT LIVER,PERITONEAL METASTASES SHOWS
BEST-IN-CLASS PFS OF 7 MONTHS

Source text for Eikon:  ID:nGNX6vMzn2 
Further company coverage:  978y.F 

 ((Reuters.Briefs@thomsonreuters.com;))